The in vivo and in vitro results performed on a CRC model demonstrated that the combined treatment between cetuximab and MEKi has synergic anti-proliferative and pro-apoptotic properties, combined with MAPK and PI3K/AKT/mTOR inhibition [165]. The gene discussed is MTOR; the disease is colorectal carcinoma.